Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Durvalumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    218 result(s) found for: Durvalumab. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003118-42 Sponsor Protocol Number: D419EC00001 Start Date*: 2019-04-16
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patien...
    Medical condition: Advanced Solid Tumors and Hematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001402-20 Sponsor Protocol Number: D910FC00001 Start Date*: 2019-11-27
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
    Medical condition: Various types of cancer ( dependent on parent study)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed) HU (Completed) PL (Completed) ES (Ongoing) GR (Completed) BE (Completed) BG (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004556-27 Sponsor Protocol Number: D933IC00003 Start Date*: 2018-04-29
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-In...
    Medical condition: Unresectable Stage IV Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10022880 Invasive bladder cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002931-35 Sponsor Protocol Number: D9108C00001 Start Date*: 2019-04-19
    Sponsor Name:MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small...
    Medical condition: Stage III non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000764-29 Sponsor Protocol Number: D933LC00001 Start Date*: 2018-11-29
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapi...
    Medical condition: First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002040-78 Sponsor Protocol Number: D8151C00001 Start Date*: 2021-11-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid...
    Medical condition: Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000336-55 Sponsor Protocol Number: D5086C00001 Start Date*: 2021-08-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Open Label, Randomised, 3 Arm, Multi Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET Driven, Unresectable and Locally A...
    Medical condition: MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078493 Papillary renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000867-10 Sponsor Protocol Number: D933QC00001 Start Date*: 2018-11-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Li...
    Medical condition: Patients with Stage I-III Limited Disease Small-Cell Lung Cancer (LD-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004112-60 Sponsor Protocol Number: D9311C00001 Start Date*: 2020-06-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or with...
    Medical condition: Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000670-37 Sponsor Protocol Number: ESR-17-13332 Start Date*: 2019-05-09
    Sponsor Name:Radboud University Medical Center
    Full Title: Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736).
    Medical condition: Patients with non-small cell lung carcinoma (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003048-22 Sponsor Protocol Number: Uni-Koeln-3571 Start Date*: 2020-06-16
    Sponsor Name:Universität zu Köln
    Full Title: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal...
    Medical condition: locally advanced esophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001173 Adenocarcinoma of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002872-42 Sponsor Protocol Number: D9100C00001 Start Date*: 2019-02-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherap...
    Medical condition: Patient with FIGO Stages IB2 to IIB Node+ and IIIA to IVA with any node. Patients must not have previously received any definitive surgical, radiation, or systemic therapy for cervical cancer and m...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001028-21 Sponsor Protocol Number: D6070C00005 Start Date*: 2018-09-19
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pa...
    Medical condition: Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003516-21 Sponsor Protocol Number: MEDI4736-NHL-001 Start Date*: 2016-04-13
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 1/2, open label, multicenter study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic l...
    Medical condition: Relapsed/refractory (R/R) lymphoma or R/R chronic lymphocytic leukemia (CLL) previously treated with at least one systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029592 Non-Hodgkin's lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000556-35 Sponsor Protocol Number: D910LC00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ...
    Medical condition: Completely Resected Stage II-III NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002997-29 Sponsor Protocol Number: D9106C00001 Start Date*: 2019-01-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lun...
    Medical condition: Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) AT (Trial now transitioned) BG (Completed) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003460-30 Sponsor Protocol Number: D9102C00001 Start Date*: 2019-03-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintena...
    Medical condition: Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) PL (Trial now transitioned) HU (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004336-31 Sponsor Protocol Number: D4194C00009 Start Date*: 2020-08-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemoth...
    Medical condition: Patients with Stage III unresectable Non-small cell lung cancer (NSCLC), who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who are treated with radiotherapy but are ineligible ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000577-36 Sponsor Protocol Number: S60379 Start Date*: 2018-08-27
    Sponsor Name:University Hospitals Leuven
    Full Title: Durvalumab (MEDI4736) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
    Medical condition: resectable, locally advanced squamous cell carcinoma of the oral cavity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004327-32 Sponsor Protocol Number: D9075C00001 Start Date*: 2022-06-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Doubleblind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable No...
    Medical condition: The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laborat...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:33:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA